Abstract
Prostate cancer is a common cancer among males in the USA and is often treated by intermittent androgen deprivation therapy. This therapy requires a patient to alternate between periods of androgen suppression treatment and no treatment. Prostate-specific antigen levels are used to track relative changes in tumor volume of prostate cancer patients undergoing intermittent androgen deprivation therapy. During this therapy, there is a pause between treatment cycles. Traditionally, continuous ordinary differential equations are used to estimate prostate-specific antigen levels. In this paper, we use dynamic equations to estimate prostate-specific antigen levels and construct a novel time scale model to account for both continuous and discrete time simultaneously. This allows us to account for breaks between treatment cycles. Using empirical data sets of prostate-specific antigen levels, a known bio-marker of prostate cancer, across multiple patients, we fit our model and use least squares to estimate two parameter values. We then compare our model to the data and find a resemblance on treatment intervals similar to our time scale.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bohner M, Peterson A (2001) Dynamic equations on time scales. Birkhäuser Boston Inc, Boston, MA, an introduction with applications. https://doi.org/10.1007/978-1-4612-0201-1
Bruchovsky N, Klotz L, Crook J, Malone S, Ludgate C, Morris WJ, Gleave ME, Goldenberg SL (2006) Final results of the canadian prospective phase ii trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters. Cancer 107(2):389–395
Everett R, Packer A, Kuang Y (2014) Can mathematical models predict the outcomes of prostate cancer patients undergoing intermittent androgen deprivation therapy? Biophys Rev Lett 9(02):173–191
Gleave M, Klotz L, Taneja SS (2007) The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer. In: Evans CP (ed) Annual meeting of the society of urologic oncology/society for basic urologic research, Elsevier, pp 81–86. https://doi.org/10.1016/j.urolonc.2008.07.025
Hilger S (1990) Analysis on measure chains: a unified approach to continuous and discrete calculus. Results Math 18(1–2):18–56. https://doi.org/10.1007/BF03323153
Hirata Y, Bruchovsky N, Aihara K (2010) Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer. J Theor Biol 264(2):517–527
Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ et al (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 368(14):1314–1325
Ideta AM, Tanaka G, Takeuchi T, Aihara K (2008) A mathematical model of intermittent androgen suppression for prostate cancer. J Nonlinear Sci 18(6):593
Klotz L, Toren P (2012) Androgen deprivation therapy in advanced prostate cancer: Is intermittent therapy the new standard of care? Curr Oncol 19(Suppl 3):S13
Kuang Y, Nagy JD, Eikenberry SE (2016) Introduction to mathematical oncology, vol 59. CRC Press, Boca Raton
Labrie F (2011) Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat Rev Urol 8(2):73
McLaren DB, McKenzie M, Duncan G, Pickles T (1998) Watchful waiting or watchful progression? Prostate specific antigen doubling times and clinical behavior in patients with early untreated prostate carcinoma. Cancer Interdiscip Int J Am Cancer Soc 82(2):342–348
Mitin T, Efstathiou JA, Shipley WU (2012) Urological cancer: the benefits of intermittent androgen-deprivation therapy. Nat Rev Clin Oncol 9(12):672
Nelson PS (2012) Molecular states underlying androgen receptor activation: a framework for therapeutics targeting androgen signaling in prostate cancer. J Clin Oncol 30(6):644–646
Portz T, Kuang Y, Nagy JD (2012) A clinical data validated mathematical model of prostate cancer growth under intermittent androgen suppression therapy. Aip Adv 2(1):011
Resnick MJ (2013) Urological cancer: walking the tightrope of survival and quality of life with adt. Nat Rev Clin Oncol 10(6):307
Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. Jama 294(2):238–244
Siegel R, Naishadham DDAJ (2013) Cancer statistics. Cancer J Clin 63(1):11–30. https://doi.org/10.3322/caac.21166
Vollmer RT, Egawa S, Kuwao S, Baba S (2002) The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 japanese men. Cancer 94(6):1692–1698
von Ende-Becker M (2018) An optimization of intermittent therapy treatment: a time scales approach. Master’s thesis, Texas Tech University
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Higgins, R., Mills, C.J. & Peace, A. A Time Scales Approach for Modeling Intermittent Hormone Therapy for Prostate Cancer. Bull Math Biol 82, 145 (2020). https://doi.org/10.1007/s11538-020-00821-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s11538-020-00821-z